ADVERTISEMENT
NCCN Guidelines for Treating Metastatic Castration-Resistant Prostate Cancer: Biomarker-Selected Patients
Atish Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discuss germline genetic testing and somatic testing and treatment modalities that have demonstrated clinical benefit in metastatic castration-resistant prostate cancer (mCRPC) for biomarker-selected patients.
Dr Choudhury is a Senior Physician at Dana-Farber Cancer Institute, Co-Director of the Prostate Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center, and Assistant Professor of Medicine at Harvard Medical School. Dr Morgans is Medical Oncologist at the Dana-Farber Cancer Institute, where I'm also the Medical Director of the Survivorship Program.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement